Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin

NCT00840450 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped Due to slow accrual

Conditions

Ovarian Cancer

Interventions

DRUG: Gleevec/Paclitaxel

Sponsor

NYU Langone Health

Collaborators

[object Object]